Professor Gilbert Greub MD-PhD
14th June 2023
A new method for detecting bacterial susceptibility to antibiotics
Scientists from EPFL and Vrije Universiteit Brussel have been working for several years on a new nanomotion based method to detect bacterial sensitivity to antibiotics. In essence, it involves “watching the bacteria dance”. Joining Stéphane Gabioud and journalist, Cécile Guérin, on Swiss radio show CQFD to discuss this new method is Professor Gilbert Greub MD-PhD, Chief Physician of Diagnostic Laboratories at the University Hospital of Vaud (CHUV) and scientific advisor to Resistell, the company commercializing this novel detection method.
24th March 2023
iM4TB announces major progress in macozinone development and new partnership with Resistell
The @Innovative Medicines for Tuberculosis (iM4TB) foundation, a Swiss non-profit fighting tuberculosis (TB), is pleased to announce a new partnership with @Resistell. The partners will harness Resistell’s proprietary Phenotech technology to further investigate iM4TB’s TB drug candidate, macozinone (PBTZ169).
27th February 2023
First patients recruited for international clinical study in Switzerland, Spain and Austria
Resistell, a leader in phenotypic nanomotion technology for measuring living cells, is proud to announce the launch of its next international, multisite clinical study, PHENOTECH-1.
19th December 2022
Resistell AG closes its series B first tranche of CHF 8.5m
Resistell AG, a leader in phenotypic nanomotion technology for measuring living cells, has taken another major step to achieving its vision by closing a first tranche of its series B financing round raising CHF 8.5M from new and existing investors.
3rd October 2022
Join us at BioJapan in Yokohama on 12-14 October 2022
Meet Resistell team at Bio Japan 2022 at Swisstech booth. Learn about World's fastest Antibiotic Susceptibility Test based on the first in class nanomotion technology platform!